Current aspects of the diagnosis and treatment of chronic gastritis associated with Helicobacter Pylori
https://doi.org/10.52485/19986173_2026_1_130
Abstract
This review discusses the role of coinfection in the development of chronic gastritis associated with Helicobacter pylori. Coinfection with Epstein-Barr virus, herpes simplex virus types 2 and 6, and opisthorchiasis aggravates the course of gastritis and reduces the effectiveness of eradication. High hopes are placed on artificial intelligence, which can compare endoscopic images of the stomach with photographs depicting various pathological processes in real time and provide a diagnosis with 82 % accuracy. According to the Maastricht VI consensus, four lines of eradication are recommended, of which the third and fourth lines are considered salvage therapy. The use of plant foods containing terpenoids, polyphenols, and alkaloids, as well as the use of probiotics in combination with antibiotics, increases the effectiveness of eradication. The development of vaccines against Helicobacter pylori holds promise
Keywords
chronic gastritis,
Helicobacter pylori,
artificial intelligence,
eradication,
antibiotic resistance,
vaccination
Supporting agencies: The study had no financial support
About the Authors
P. V. Koydan
Chita State Medical Academy
Russian Federation
Russian Federation
resident
Department of Pediatrics
672000; 39a Gorky St.; Chita
V. A. Shcherbak
Chita State Medical Academy
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Head of Department
Postgraduate training; Pediatric Department
672000; 39a Gorky St.; Chita
Author ID RSCI 497238, Author ID Scopus 56175430800, Researcher ID WoS K-4626-2017
References
1. Sapozhnikov V.G., Burmykin V.V. Certain diagnostic directions for gastrointestinal tract pathology in children. Tula. Tula State University. 2025. 225 p. (in Russian).
2. Shcherbak V.A., Luzina E.V., Rozhkova N.G. Prevalence of Helicobacter pylori infection in families of gastroenterologists. Siberian Medical Review. 2023. 2. 83-89. DOI: 10.20333/25000136-2023-2-83-89. (in Russian).
3. Petrova E.E., Karnaeva E.V., Shcherbak V.A., Aksenova T.A. Current concepts of the etiology and pathogenesis of gastroduodenitis (review). The Siberian Journal of Clinical and Experimental Medicine. 2025. DOI: 10.29001/2073-8552-2024-695. [Internet]. Available from https://www.sibjcem.ru/jour/article/view/2525 (cited 19. 11. 2025).
4. Malfertheiner P., Megraud F., Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/ Florence consensus report. Gut. 2022. 71 (9). 1724–1762. doi: 10.1136/gutjnl-2022-327745.
5. Maev I.V., Andreev D.N., Samsonov A.A., Fomenko A.K. Helicobacter pylori-associated chronic gastritis: the current state of the problem. Medical Council. 2022. 16. 15. 35–45. doi: 10.21518/2079-701X-2022-16-15-35-45. (in Russian).
6. Karbalaei M., Talebi Bezmin Abadi A., Keikha M. Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis. BMC Infect Dis. 2022 Jun 25. 22 (1). 573. doi: 10.1186/s12879-022-07546-5.
7. Tran S.C., Bryant K.N., Cover T.L. The Helicobacter pylori cag pathogenicity island as a determinant of gastric cancer risk. Gut Microbes. 2024. 16. 1. 2314201. doi: 10.1080/19490976.2024.2314201.
8. Vshivkov V.A., Polivanova T.V., Kasparov E.V. Expression of CDX2, CK20, and CK7 in the gastric mucosal epithelium of schoolchildren with CagA H. pylori-associated gastritis. Experimental and Clinical Gastroenterology. 2024. 226. 6. 31–37. doi: 10.31146/1682-8658-ecg-226-6-31-37. (in Russian).
9. Dubskaya E.E., Afanasenkova T.E., Bazhenov S.M. Persistence of Epstein-Barr virus in the gastric mucosa of patients with chronic Helicobacter pylori-induced gastritis with gastric erosions and its impact on the course of the disease depending on the therapy. Doctor. 2021. 10. 24. 46–49. DOI: 10.51793/OS.2021.24.10.008. (in Russian).
10. Dávila-Collado R., Jarquín-Durán O., Dong L. Th., Espinoza J. L. Epstein-Barr Virus and Helicobacter Pylori Co-Infection in Non-Malignant Gastroduodenal Disorders. Pathogens. 2020. 9 (2). 104. doi: 10.3390/pathogens9020104.
11. Luzina E.V., Lareva N.V., Lazebnik L.B., et al. Co-infection with Helicobacter pylori and herpesviruses in chronic gastritis. Experimental and Clinical Gastroenterology. 2023. 220. 12. 27–35. DOI: 10.31146/1682-8658-ecg-220-12-27-35. (in Russian).
12. Sarshari B., Mohebbi S.R., Ravanshad M. et al. Detection and quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus-6 in stomach frozen tissue of chronic gastritis and gastric cancer patients. Microbiol Immunol. 2022. Aug; 66 (8): 379–385. doi: 10.1111/1348-0421.13013.
13. Strezhnev I.A. Opisthorchiasis: epidemiology and factors influencing its spread. Bulletin of the Medical Institute "REAVIZ". 2023. 13. 2. 159–160. (in Russian).
14. Bibik O.I., Pomytkina T.E., Pivovar O.I. Study of the features of the combined course of opisthorchiasis and helicobacteriosis. Russian Journal of Parasitology. 2021. 15. 1. 79–84. doi: 10.31016/1998-8435-2021-15-1-79-84. (in Russian).
15. Feldman M., Jensen P.J., Howden C.W. Gastritis and Gastropathy. In: Feldman M., Friedman L., Brandt L. (eds.). Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10<sup>th</sup> ed. Philadelphia: Saunders/Elsevier; 2020. Available at: https://www.ncbi.nlm.nih.gov/nlmcatalog/101500948.
16. Shcherbak V.A. Syndrome of dyspepsia in children of the Transbaikal territory. Transbaikalian Medical Bulletin. 2022. 3. 1–8. DOI: 10.52485/19986173_2022_3_1.
17. Ivashkin V.T., Maev I.V., Lapina T.L., et al. Clinical guidelines of the Russian Gastroenterological Association and the Endoscopic Society RENDO for the diagnosis and treatment of gastritis and duodenitis. Russian Journal of Gastroenterology, Hepatology, Proctology. 2021. 31. 4. 70–99. doi: 10.22416/1382-4376-2021-31-4-70-99. (in Russian).
18. Bordin D.S., Shengelia M.I., Ivanova V.A., Voynovan I.N. Helicobacter pylori: clinical significance and diagnostic principles. Infectious Diseases: News, Opinions, Training. 2022. 11. 1. 119–129. DOI: 10.33029/2305-3496-2022-11-1-119-129. (in Russian).
19. Makristathis A., Hirschl A.M., Mégraud F., Bessède E. Review: Diagnosis of Helicobacter pylori infection. Helicobacter. 2019. 24. 1. e12641. DOI: 10.1111/hel.12641.
20. Bang C.S., Lee J.J., Baik G.H. Artificial Intelligence for the Prediction of Helicobacter Pylori infection in endoscopic images : systematic review and metaanalysis of diagnostic test accuracy. J. Med. Internet. Res. 2020. 22. 9. e21983. DOI: 10.2196/21983.
21. Kornienko E.A., Kolomina E.O., Parolova N.I., et al. Use of rapid urease tests in the semiquantitative assessment of Helicobacter pylori infection in pediatric practice. Experimental and Clinical Gastroenterology. 2023. 215. 7. 19–24. doi: 10.31146/1682-8658-ecg-215-7-19-24. (in Russian).
22. Leonardi M., La Marca G., Pajola B. et al. Assessment of real-time PCR for Helicobacter pylori DNA detection in stool with co-infection of intestinal parasites: a comparative study of DNA extraction methods. BMC Microbiol. 2020. 20. 131. doi: 10.1186/s12866-020-01824-5.
23. Jaroń K., Pietrzak A., Daniluk J., Adrych K. et al. Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology. Prz Gastroenterol. 2023. 18 (3). 225–248. doi: 10.5114/pg.2023.131998.
24. Elbehiry A., Marzouk E., Aldubaib M. et al. Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics (Basel). 2023. 12 (2). 191. doi: 10.3390/antibiotics12020191.
25. Andreev D.N., Bordin D.S., Nikolskaya K.A., Dzhafarova A.R., Cherenkova V.V. Current trends in eradication therapy for Helicobacter pylori infection. Medical Council. 2023. 17. 8. 18–27. doi: 10.21518/ms2023-134. (in Russian).
26. Alavinejad P., Mohamadi S., Rezaei M.J. et al. High-dose amoxicillin and pantoprazole regimen for Helicobacter pylori eradication: a multi-center, multinational randomized controlled trial. Prz Gastroenterol. 2025. 20 (2). 178–184. doi: 10.5114/pg.2025.151887.
27. Khan M.S.A., Khundmiri S.U.K., Khundmiri S.R., Al-Sanea M.M., Mok P.L. Fruit-Derived Polysaccharides and Terpenoids: Recent Update on the Gastroprotective Effects and Mechanisms. Front Pharmacol. 2018 Jun. 22; 9: 569. doi: 10.3389/fphar.2018.00569.
28. Al-Sayed E., Gad H.A., El-Kersh D.M. Characterization of Four Piper Essential Oils (GC/MS and ATR-IR) Coupled to Chemometrics and Their anti-Helicobacter pylori Activity. ACS Omega. 2021 Sep. 22; 6 (39): 25652–25663. doi: 10.1021/acsomega.1c03777.
29. Shipa S.J., Khandokar L., Bari M.S., Qais N., Rashid M.A., Haque M.A., Mohamed I.N. An insight into the anti-ulcerogenic potentials of medicinal herbs and their bioactive metabolites. J Ethnopharmacol. 2022 Jul. 15; 293: 115245. doi: 10.1016/j.jep.2022.115245.
30. Behzadi P., Dodero V.I., Golubnitschaja O. Systemic Inflammation as a Health-Related Communication Tool Between the Human Host and Gut Microbiota in the Framework of Predictive, Preventive, and Personalized Medicine. In: Wang, W. (eds) All Around Suboptimal Health. Advances in Predictive, Preventive and Personalized Medicine. 2024. 18. Springer, Cham. doi: 10.1007/978-3-031-46891-9_15.
31. Yuan Z., Xiao S., Li S. et al. The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter. 2021. 26:e12848. doi: 10.1111/hel.12848.
32. Rugge M., Genta R.M., Malfertheiner P. et al. RЕ.GА.ІN.: the Real-world Gastritis Initiative-updating the updates. Gut. 2024. Feb. 23. 73 (3). 407–441.
33. Yunle K., Tong W., Jiyang L., Guojun W. Advances in Helicobacter pylori vaccine research: from candidate antigens to adjuvants - a review. Helicobacter. 2024. 29:e13034. doi: 10.1111/hel.13034.
34. Katsande P.M., Nguyen V.D., Nguyen T.L. P. et al. Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines. Helicobacter. 2023. 28:e12997. doi: 10.1111/hel.12997.
35. Jiang F., Guo C.G., Cheung K.S. Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: a 15-year population-based study. Helicobacter. 2022. 27:e12893. doi: 10.1111/hel.12893.
36. Uspensky Yu.P., Baryshnikova N.V., Ermoolenko E.I., Suvorov A.N., Svarval A.V. Vaccine against Helicobacter pylori: myth or reality? Infection and Immunity. 2019. 9. 3–4. 457–466. doi: 10.15789/2220-7619-2019-3-4-457-466. (in Russian).
37. Di J., Zhang J., Cao L. et al. Hydrogen peroxide-mediated oxygen enrichment eradicates Helicobacter pylori in vitro and in vivo. Antimicrob. Agents Chemother. 2020. 64. 2192. doi: 10.1128/AAC.02192-19.
38. Zhang X., He Y., Zhang X. et al. Sustained exposure to Helicobacter pylori induces immune tolerance by desensitizing TLR6. Gastric Cancer. 2024. 27. 324–342. doi: 10.1007/s10120-023-01461-7.
39. Tang W., Guan M., Li Z., Pan W., Wang Z. A2BR facilitates the pathogenesis of H. pylori-associated GU by inducing oxidative stress through p38 MAPK phosphorylation. Heliyon. 2023 Oct. 20; 9 (11): e21004. doi: 10.1016/j.heliyon.2023.e21004.
40. He H., Liu J., Li L., Qian G., Hao D., Li M., Zhang Y., Hong X., Xu J., Yan D. Helicobacter pylori CagA Interacts with SHP-1 to Suppress the Immune Response by Targeting TRAF6 for K63-Linked Ubiquitination. J Immunol. 2021 Mar. 15; 206 (6): 1161–1170. doi: 10.4049/jimmunol.2000234.
Review
For citations:
Koydan P.V., Shcherbak V.A. Current aspects of the diagnosis and treatment of chronic gastritis associated with Helicobacter Pylori. Transbaikalian Medical Bulletin. 2026;(1):130-139. (In Russ.) https://doi.org/10.52485/19986173_2026_1_130
Views:
243
JATS XML
Email this article 